Accéder au contenu
Merck

Mesocortical BDNF signaling mediates antidepressive-like effects of lithium.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology (2020-05-20)
Di Liu, Qian-Qian Tang, Di Wang, Su-Pei Song, Xiao-Na Yang, Su-Wan Hu, Zhi-Yong Wang, Zheng Xu, He Liu, Jun-Xia Yang, Sarah E Montgomery, Hongxing Zhang, Ming-Hu Han, Hai-Lei Ding, Jun-Li Cao
RÉSUMÉ

Lithium has been used to treat major depressive disorder, yet the neural circuit mechanisms underlying this therapeutic effect remain unknown. Here, we demonstrated that the ventral tegmental area (VTA) dopamine (DA) neurons that project to the medial prefrontal cortex (mPFC), but not to nucleus accumbens (NAc), contributed to the antidepressive-like effects of lithium. Projection-specific electrophysiological recordings revealed that high concentrations of lithium increased firing rates in mPFC-, but not NAc-, projecting VTA DA neurons in mice treated with chronic unpredictable mild stress (CMS). In parallel, chronic administration of high-dose lithium in CMS mice restored the firing properties of mPFC-projecting DA neurons, and also rescued CMS-induced depressive-like behaviors. Nevertheless, chronic lithium treatment was insufficient to change the basal firing rates in NAc-projecting VTA DA neurons. Furthermore, chemogenetic activation of mPFC-, but not NAc-, projecting VTA DA neurons mimicked the antidepressive-like effects of lithium in CMS mice. Chemogenetic downregulation of VTA-mPFC DA neurons' firing activity abolished the antidepressive-like effects of lithium in CMS mice. Finally, we found that the antidepressant-like effects induced by high-dose lithium were mediated by BNDF signaling in the mesocortical DA circuit. Together, these results demonstrated the role of mesocortical DA projection in antidepressive-like effects of lithium and established a circuit foundation for lithium-based antidepressive treatment.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
TrkB/Fc Chimera human, >90% (SDS-PAGE), recombinant, expressed in NSO cells, lyophilized powder